In our in vivo xenograft study, the combination of curcumin and taxol had therapeutic effects comparable with taxol and herceptin, one of the current preferred regimens for HER-2-overexpressed breast cancer (Figure 6(b)). Here, ERBB2 is linked to breast carcinoma.